Introduction
Assembly Biosciences (ASMB) is a small-cap biotech company focused on the development of HBV therapeutics and microbiome-based therapies. The company has decidedly focused on a new and promising drug target which has already attracted many startup biotech companies and big pharma- the HBV core protein. With an FDA-fast track designation, Assembly has taken the lead position in the race to bring the world's first HBV core inhibitor to market. It's first-generation compound, ABI-H0731 is currently in phase 2a testing and has been shown to be safe and effective in early clinical testing.